IMR Press / FBL / Volume 18 / Issue 3 / DOI: 10.2741/4143

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review
Cancer stem cell in the progression and therapy of pancreatic cancer
Show Less
1 Department of Gastroenterology, Fengxian Branch of 6th Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201400, P. R. China
Academic Editor:Wei Qin
Front. Biosci. (Landmark Ed) 2013, 18(3), 795–802;
Published: 1 June 2013
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)

Pancreatic cancer (PC) is an aggressive malignancy with a high incidence of distant metastasis and mortality. Emerging evidence has demonstrated that pancreatic cancer stem cells (CSCs), which have the potential to self-renew and are pluripotent, are crucially important in the progression and therapy of PC. The origin of pancreatic CSCs was suggested to be pancreatic acinar cells, centroacinar cells, or acinar-ductal metaplasia. And several CSC-specific markers for pancreatic cancer have been reported, including CD133, CD24, CD44 and CXCR4. Several studies reported the molecular mechanisms regulating human pancreatic CSCs characteristics. In the progression of PC, CSCs are linked with the aggressiveness of PC with association of epithelial to mesenchymal transition (EMT). In the therapy of PC, especially chemotherapy, CSCs offer new insight into PC therapy, especially the mechanism of drug resistance. Therefore, strategies for modulating and treating CSCs can lead to novel targeted therapies for pancreatic cancer.

Pancreatic cancer
cancer stem cells
mesenchymal transition
pancreatic stellate cells
Back to top